-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Nqf+KNuKtECaL+4gMC+lplq6oT/9s6ySBDx/zs9srBpED5N113uLztndm8KZatB3
 OnLtBIZaaj8C+IHMPMttyw==

<SEC-DOCUMENT>0001193125-10-059580.txt : 20100317
<SEC-HEADER>0001193125-10-059580.hdr.sgml : 20100317
<ACCEPTANCE-DATETIME>20100317163543
ACCESSION NUMBER:		0001193125-10-059580
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20100312
ITEM INFORMATION:		Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100317
DATE AS OF CHANGE:		20100317

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		10689131

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K </B>
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman"
SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of 1934 </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): March&nbsp;17, 2010 (March 12, 2010) </B></FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"
ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ARCA biopharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as
Specified in Charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 200,
Broomfield, CO 80021 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman"
SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;3.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice of Delisting or Failure to Satisfy a Continued Listing Rule of Standard; Transfer of Listing. </B></FONT></TD></TR></TABLE> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;12, 2010, ARCA biopharma, Inc. (&#147;ARCA&#148;) received a notice from the NASDAQ Stock Market (the &#147;Notice&#148;)
indicating that ARCA&#146;s stockholders&#146; equity did not meet the minimum requirement of $10,000,000 for continued listing as set forth in Continued Listing Standards for Primary Equity Securities Rule 5450(b). For the year ended
December&nbsp;31, 2009, and as reported on ARCA&#146;s Annual Report on Form 10-K, ARCA&#146;s stockholders&#146; equity was $7,412,000. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Under NASDAQ Rules, ARCA has 45 calendar days to submit a plan that defines how ARCA will regain compliance. ARCA plans to respond by submitting an appropriate plan to NASDAQ within the 45&nbsp;day
deadline. If the plan is accepted by NASDAQ, ARCA will receive an extension of up to 180 calendar days from March&nbsp;12, 2010,&nbsp;September&nbsp;8, 2010, to establish evidence of compliance. If the plan is not accepted, ARCA will receive written
notice from NASDAQ that ARCA&#146;s securities will be delisted. Upon receipt of that notice, ARCA may appeal the NASDAQ staff&#146;s determination to delist ARCA&#146;s securities to a Listing Qualifications Panel. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As required by NASDAQ Listing Rule 5810(b), ARCA has issued a press release reporting the receipt of the Notice and the NASDAQ rules upon
which the Notice is based. A copy of the press release is attached hereto as Exhibit 99.1 and the information contained therein is incorporated herein by reference. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s common stock is listed on the NASDAQ Global Market. To maintain that listing, the Company must satisfy minimum financial and other continued listing requirements. For example, NASDAQ
rules require that the Company maintain a minimum stockholders&#146; equity of $10,000,000. On March&nbsp;12, 2010, NASDAQ delivered a notice regarding the Company&#146;s noncompliance with NASDAQ&#146;s minimum stockholders&#146; equity
requirement. The Company plans to respond to the notice by submitting a plan of compliance to NASDAQ within 45 days of the notice. If the plan is accepted by NASDAQ, the Company will receive an extension of up to 180 calendar days from
March&nbsp;12, 2010,&nbsp;September&nbsp;8, 2010, to establish evidence of compliance. There can be no assurance that these actions will be successful in maintaining the Company&#146;s listing on NASDAQ Global Market for the Company&#146;s common
stock. If NASDAQ does not accept the Company&#146;s plan for compliance or if the Company is unable to comply with all applicable listing requirements of NASDAQ Global Markets, the Company&#146;s common stock could be delisted from NASDAQ Global
Markets. This could impair the liquidity and market price of the Company&#146;s common stock. In addition, the delisting of the Company&#146;s common stock from a national exchange could materially adversely affect the Company&#146;s access to the
capital markets, and any limitation on market liquidity or reduction in the price of the Company&#146;s common stock as a result of that delisting could adversely affect the Company&#146;s ability to raise capital, if needed, on terms acceptable to
the Company or at all. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This current report on Form 8-K contains forward-looking statements, including without limitation
statements related to ARCA&#146;s intentions to regain compliance with NASDAQ rules. Words such as &#147;will,&#148; &#147;plans to&#148; and similar expressions are intended to identify forward-looking statements. These forward-looking statements
are based upon ARCA&#146;s current expectations. Forward-looking statements involve risks and uncertainties. These and other risk factors are discussed under &#147;Risk Factors&#148; and elsewhere in ARCA annual report on Form 10-K for the year
ended December&nbsp;31, 2009 and other filings with the Securities and Exchange Commission. ARCA expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to
reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman"
SIZE="2">(d) Exhibits </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA Announces Receipt of NASDAQ Notice per NASDAQ Rule 5810(b)&#148;, dated March&nbsp;17, 2010.</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: March&nbsp;17, 2010 </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA biopharma, Inc.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman"
SIZE="2">(Registrant)</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;M<SMALL>ICHAEL</SMALL> R. B<SMALL>RISTOW</SMALL>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Michael R. Bristow</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>President and Chief Executive Officer</B></FONT></TD></TR></TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA Announces Receipt of NASDAQ Notice per NASDAQ Rule 5810(b)&#148;, dated March&nbsp;17, 2010.</FONT></TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right">

<IMG SRC="g65062g88t34.jpg" ALT="LOGO"> </P>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman"
SIZE="2">Derek Cole </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Investor Relations&nbsp;&amp; Corporate Communications </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">720.940.2163 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>derek.cole@arcabiopharma.com</U>
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA Announces Receipt of NASDAQ Notice per NASDAQ Rule 5810(b) </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Broomfield, CO, March&nbsp;17, 2010</I> &#150; ARCA biopharma, Inc. (NASDAQ: ABIO), a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular
disease, today announced, as required by NASDAQ Marketplace Rule 5810(b), that on March&nbsp;12, 2010, it received a notice from the NASDAQ Stock Market indicating that the Company&#146;s stockholders&#146; equity as of December&nbsp;31, 2009, did
not meet the minimum requirement of $10,000,000 for continued listing as set forth in Continued Listing Standards for Primary Equity Securities Rule 5450(b). This notification does not affect the listing of the Company&#146;s common stock at this
time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under NASDAQ Rules, the Company has 45 calendar days to submit a plan that defines how the Company will regain compliance. The Company
plans to respond by submitting an appropriate plan to NASDAQ within the 45&nbsp;day deadline. If the plan is accepted by NASDAQ, the Company will receive an extension of up to 180 calendar days from March&nbsp;12, 2010,&nbsp;September&nbsp;8, 2010,
to establish evidence of compliance. If the plan is not accepted, the Company will receive written notice from NASDAQ that the Company&#146;s securities will be delisted. Upon receipt of that notice, the Company may appeal the NASDAQ staff&#146;s
determination to delist the Company&#146;s securities to a Listing Qualifications Panel. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About ARCA biopharma </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA biopharma is dedicated to developing genetically targeted therapies for heart failure and other cardiovascular disease. The
Company&#146;s lead product candidate, Gencaro</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">
(bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for heart failure. ARCA has identified common genetic variations that it believes predict individual patient response to
Gencaro, giving it the potential to be the first genetically-targeted heart failure treatment. ARCA is collaborating with Laboratory Corporation of America to develop the companion genetic test for Gencaro. For more information please visit
<U>www.arcabiopharma.com</U>. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Safe Harbor Statement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This press release contains &#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not
limited to, statements related to ARCA&#146;s intentions to comply with NASDAQ rules the impact of genetic biomarkers on patient response to Gencaro and the use of such biomarkers to predict therapeutic response. Such statements are based on
management&#146;s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the
risks and uncertainties associated with: the Company&#146;s financial resources and whether they will be sufficient to meet the Company&#146;s business objectives and operational requirements; the Company&#146;s ability to complete a strategic
transaction to support the continued development Gencaro, and/or obtain additional financing; the Company&#146;s ability to identify, develop and achieve commercial success for products and technologies; risks related to the drug discovery and the
regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA&#146;s filings with the SEC, including without limitation the Company&#146;s
annual report on Form 10-K for the year ended December&nbsp;31, 2009 and any subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g65062g88t34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g65062g88t34.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`2`#4`P$1``(1`0,1`?_$`+<````&`P$!`0``````
M```````&!P@)"@$$!0(#"P$!`0`"`@,!`0````````````$"`P<(!08*"000
M``$$`@$#`P("!@8(!P$```,!`@0%!@<1`!(((1,),10B%4%183)2%G&1T9(7
M"H%"([0E-748L7(S4R0T)AD1``$#`@4#`@,%!`<)``````$``@,1!"$Q$@4&
M05$'(A-A<3*!0B,5")%2%`EB@M(S0R06H='Q<I)3DS0F_]H`#`,!``(1`Q$`
M/P"TYY8^5N4Q\IM=7ZPMC44&B*^MR?)*Y49;6=LB(DNJJYGJ^O@5RN]HI!=I
MBG1R(YK&_C_)#]87ZO\`EEMRV[\5>*[Q^W;?MSC#?7L-!<37%![EO!)B88H:
MZ))&4E?*'-:]K&>OG_QWX\V^3;X]^WZ,32S#5%$[Z&LZ/>/O.=FT'TAM"02<
M&&PZ>UR"<Z7:'FSCF,CI<F48\F63EW)'$.=SS/+PJKZJOKU^<-M:[UR;<S<W
MSKBYF?)^+)(Y[Y'8^JKGESB[/,YKEZ6YMK&'VX&L8P#````=L!A1*E4Z?FON
MH=48/<4UC!BIPWEIF2S!]@K.45'#.$S7M_6UR=<L;-X+WRXW^WVJZ!,CKN*/
M+TN;(]FEP[M>QP<WN"%Z]<\IA;;.N&'TACC\J`U!^1!!^(6B?5$IYS#:)R#C
M,DR)+^U40,6&UY#O5>%1OX6]K?UO<U/T]>.F\+[TVY>R/7[,0D?(:'TQQ`N>
M?V#2/Z3FCJMK.30A@)(U.(`'Q=E_O/P!2<K%R#%9[+"FG653/CN5X)59+DPY
M@5;R[D<B,\94[43GZ]<;V\W)N(;HV\VR:[L=RC-62P2212-IC@^,M<*?.G=>
M=UV6XP&&Y;'+"[,.`<T_8:A25>(7E+D.;73-6;*G):74B+(D8GE!FC%.LGP1
M./+I+CVVL%)FI$&\L>0C6O(@WL)W.[7+^K?Z+_U;<CYWOC?$OE"<7>^20O?M
M]\X!LLYB;KDMKC2`U\HC#I(I@&N>&/;)J?I<[@SR3X_L]JM3O^QL]NU#@)HA
MBUNHT#V5Q#=1#7-Q`J"*"H$BW7Z9KA1#HB'1%&-2_)3@]W\E=[X`1JJM6/4Z
M]+(!L!MH]\B;N6N@CRRZUTV![;838L#!C*3W?<4ZV,<P.WT3HLM/IJI.>BQ0
MZ(H\O*3R]\E_'"URZWH?`K/-Y::Q2L!;OVAKK;V#+;GKQ50+"]ER=82*T^7Q
M`T<AQQO4;9'>("F3AB\(60`/7%1O:Z_S"%%N3,<=UQI[PCW?L78F5G+&Q_$:
M7-L*=,LC`C%FR'C.V*88(4."`AY$DR"!'"-SR.:U%7HKH^*>7E/GGYM8!0S,
MOS7XH=RLQ2KC$G6Q\'WQJ78>3U\`#5))E)A^/A);6'VX6J]S(Z$<B(J^B(J]
M%-([I3/##Y1_%'SBGFQ7661W.);1BP9%C(U1LFOC8_E\J#":UTZ;CQ(LZRHL
MIC0457';!EED1V(KRA&U.>B%I"D7Z+%%C,\UQ#7.+7F<9]D]%AF'8U!)9W^3
MY-:1*:CJ((N$=(G6,XH8P&J]R-:BN[GO<C6HKE1%(H@Q_,+$WAL"UU?\?_BW
MM;S`NJ0B!NL^?,A:BT]2H5[FQYT[+LJAR9@(4A&\B^[BP"26HJ@0J)ST6>FF
M)*6.3L;Y?&UCKJ/XQ>%+R>W[S<,7R%V,[(D3T=]HMX_7\?&'2^/P]W>T/=Z]
MW'13T?%,+V3\Z6Y?&C.XFL_++X^LLU=E,AX7#D0-LPY=-:5JRQQ9-[C%E)PM
M]+DM1%5_+R0YYD8J=CU8]>.JLM((J"K%X#BD@!)`]"`D@#("1OT>(XVE&]/V
M.8]%ZBUKZ]$25[RV]BN@=.[+W5F\AL?%M8X;>9?:I[C1$F-J81#0ZF(YR*BV
M%U8>U#C-X_&<[&_IZ*@5-$W#X[O,F'YU>,6,[S?0P,1RIUYD>(9]AU9./90<
M9RK'YW*1(<V6P4J3#L:";!G"<1C7=LKM]>WHJX4-$^/HL4.B*NQ'I9^1Y??%
M:PDZ2:_MR%:U4-**]UC(>4OM<J8JN55Y[45>OF*GV7=.6\VOXX0ZXNI-QN7/
M`(=(XF9Y<=%=3JDXZ0>J[JNNH=OVR$&C(Q$P#H!Z0`*Y#[4\36F`UMV@:6P5
ME5=KVCJ[&6QPXQS>B,J;EKF^X!2+Z`DHG<QRHPB.8K59WD\3>-MHW6*+8MRT
MVO(J!MO-("&.=]VWNA2K2[*&>A+#2.0.86EG%F_;S/`YUS#5]I]]HS']-G>G
MWFY',4-077UV$TM(;!)^3RJZAO,>G,AV=?-,U9=E65$ITBIL(H`H8LA!L5L?
MO1.TC&-X7\*]=PMMX/LFPS<>W/ELUMMV_;9<"*>&9XUSPVTA?;S1L9J+](TP
MZAZ7-:VA]&/'TVYW-RV[AL&OFM9F5:X#!CGBCVDF@&-74S!)[K5F:L%*Q^TC
MXVL.XLLEO/9D28Q6)'J<=BG+8";-*1K'1$FRFB(57-^@D:G*HJ+_`"7?BB.Z
MX[=V_%C!?;INFX:7R,<-%O91N=*T2EU#'[LGMO>2,F-8*D$'./?2R[C?>ZHH
M8(J@$8OD(#<!UH*@?,DIH>R\(JXRFI:!KK4S.X<^V"`CGV9V_O@JX[4<4-2%
MZ<-<J>Y(5.]W#>UB=+/+?CO9VQR[+QEO\7=MJ)KAC"3.\9LMV`%S;9IR/US$
M:WT9I8.2-@W>X<6W%X?;8?I82/2.[CD7G]C<AC4I"]05<S'_`"!U0UR.C&_Q
M`H`/'WM0K&'F,`5A&-<KA^X$SFJCN%7GCCKKYX%VW<.._J.XA9W/X5RWD=JW
M3J&L-?)H<'-!);5KB"'4-"00O<^37$5[PW<7-]3?X.0UZ8-J*?(CHI[U^J_T
M]?1B<UU`&2QU$2$^3F^<9\8?'_;6_<N<UU/K#"[;(V0U<K7W%R,21<;Q^.J?
MB65D&0R8L(7'KWG1?T=%0*FBHQ>16L=_^!6_?$WRPSJSL+O9^WJ?&/+FYE3!
MO$Z/LN=EQ\DV+KF47AJE^VK+B&"0UWK[=D\:IVM1.KFMH((HK\&N<^QO:NO\
M(V;A\QEABFP<3Q_,\=F,<QR'I\DJXMM`5W8JM:5H)2->WZL>BM7U3J+210T1
MSZ(M"U:U]5:,>U'L?66#7M<G+7-=#,CFN3]**B\+T146_@C&Q/DRQ-$8U$#@
M&\?:3M3_`&?;4>VWL_@X&JM]/T+QU5M=]*O:(JHJ*GU3J+4OS_\`S90_CC\O
M.R;C2*)2VV(>2F!YMBD.A$@1Q<CRP6(9/=4D2'&:C$BVEOD4R,6,UO80,IXN
MWM=QU5N&+<5^@`Y43ESE0;43O>KU1K1HC>Y_<[Z(T?KROTX3J+2J27F]Y-[4
M^6[SFPOQ$TO?2:S1$'99,)P2+&]Y]1>'HG3/YYWMED8*I^;QZJJKITFH`1%'
M'KPL5B-/**Y:MH&D5ZJWOXW^.6J?%/46+:7TYCL>@Q/&HC$D2.P;KG*+PHQI
M;99E-BC&FM\CNY#/=.8GHU.T8T8(8QMBUDDFI2Z]%$RWS[\/,.\V_&K/M/W]
M;6?SC^2V=SJ+*Y@V#F83LJ'!,_';2+8HQYX=;8RVMAV;&]S#P#$:YJJC%:5:
M:'X)Q&F*O,*/3VJ*380H0,^I=;8-49N&MG?FE</+:S&:R#D+8%E[0/OX?YL`
MJC-V,]QG#N$YZ(<TI7110J?*=7Y)Y:;'T+\9VN<C)C\_;<+*M[;OO8HU/_+&
MJ]85\S^1XUFQJN']KE^TEB#:PC?5\)B_1>BS;@-2B:_R^6^[C3WDSN'P[S]2
MT[ME1K2PJJ>:KF+5;AU&2;7Y/3#&5S4#)M\6%+]SA.Y[J<:<<\=55XPJKB'4
M6M#HB@6PRJ%*R:U5T^MC*MW8JBRY!1=B_F!U155D<JHJ+^KZ=?.5P#9X;_G-
M\^2YM(G?F$Q_$>YI'XS\Z,=0CX+MWN]RZ/;XZ,>X>TW(`_='Q"DKUNAAU3UN
M+G",NA0J^7*#6RI#K&^YAQ"R1QZR6:&"=WN47:@W$<Q$^B)U^KOC5L[-K?\`
MG=]L&]6$%O(]L$C_`'KS\*-SPRWD=$R6I+:!A>YH'T@+@C>=+IQ_#1W5O*]X
M!<!IC]1`)>`2WKG0'N4AVJ<O3+)S\GR"5]Y9W)UG33&=W*CC+W,CC15X%&BC
M5!B8GX6,:B(G77KQ#S?_`%M=#F'))O?W6_D,LKG')SC70!]UD;:,8P4#6M`"
M]KY%MOY;'^7V3=,$0TM`[#J>Y)Q)ZE.SL<AH8?Y:2O:Q2$*"')"WU29&ED9'
MD1"-:OXV'$16\?K5%3UXZ[B[ER;CEF;.7:FCW7N9%(P92LD<&/C<.H>UQ%.]
M"*$!<>PV=W+K$M=(!(/8C$'["DKV[#D(&?7U^2X+1U3'%#^44TQU?),-CG-[
M+,D6`25,,G'XV/*K$=]&]<6>8;.Y9'<;9MNZ\>V_9P7-_AK60PO<!44G<R(R
M2._>:Y^@&M&KSO'I&:F330W4MQ@=;QJ`_P"6KJ`=B!7XIBF%UPXF^M4JR7`/
MV[#QE?\`XAGD[O\`B@?W4<$7]*_3TZ_.K@&U0V'ZFN'F*>UD_P#I;+"-Y=7\
M<958W_@N7]RG,O#MQJUX_P`E+]0I]T_$J;Q?JO\`2O7T`G-=51DL=150=?(Y
MDU9Y+^8'B%\=[+>!&P5F1P_*+RC)+L8T&"FO->G-)PG"[*28@VM7*[F,7O`Y
M>[DL,O':G/19MP!<M+YW-08;O;PIG9UC5YBUCG/CKD<38U/'@WE3(GR<-FL9
MC^P*F)'CRGD(-E/)#8J-J*KEJVHB*O'1&5KBBS_E[_)?_%+Q2R'05[8>_E7C
MCDSH=.(Q&K(/K#.C3KS&7#:Y?=(&EOQ6D#TY:(`X[?3E.B/&-5/QT6"TK+_E
MEE_TZ?\`[H;HBH`_$EN"KT5YYTFQ;G#-G9[7P,3VY6&QW4."VNQLV(MM"4#9
M\;%:7_B,JM@=BOE%&CO98J*J+SU5N=DK$FY_\P/XK:[BWU!A^LM[Y)MBM(E=
M'PK/<&33\"KNSHQH0YK99E8"M\=A1WF:\[DKC/07+D1&_BZE%AH/V(G>$'Q'
M9O/\AYWGMYUY3B.:;@R?,I.W<4UA@,YEW@]!EEN=+*FR._R0:?89`W&`N$E-
M7UZEKX_L`,Z5)[&M2H784"EU\W\TMM=^''E+F]"0HKO&]";2LJF0%7(>+8MQ
M"T%%F"<W\32Q#%0K53Z*WGJ+%N+@JGO^7.P^IN?-K-[^:)A9N!>/&43:)2(C
MG`F7N687CTJ4-5]6E2JD&%W?7L,Y/TKU2MC\E=EZBU(=$0Z(AT1:%K:UM%5V
M=Y=38]934M?-M[>RED:&)7U=;&+,GSI1G?A%'B1`O(]R^C6M5>B*$KXMLKJM
M][2\NOD4SN^I:F5Y`9__`(6:-K+NYK(-C0>/FI9#ZVF]N-)D!+%9DMNQI9#4
M1J$DPG$X7O15%9NJ``H.OE2IS^%ORCT/DSJ"=62H&77F'^2&/_DMA%G0W997
M6B5FS<<E$@E(-K<AGUICR!NX[PW*HO**O563<6T5U;7&?XWM;7V#[.PZ8V?B
MFPL3Q_,\=EM<QWO4^25<6V@J_P!MSFL,P$I&D;SRPC5:OJB]1:CA@CGT15]\
M9L8<;*;C[R20(FWEFCF`%[T@B)8'Y0:$>$#?3]+G^B_H7KYI^,[E8[9SN]DW
M"9T<!W";!C=3S^,[Z:EK!\W.S^Z5W(W&WDEVZ,1-!=[3<S0?2.P)_8/M4B&H
M,Q`I1QL<IZBL&`/W%ME&0E6TDP*Y.&F.4CTB5T)"<]C!"%WE>Y&(KE7K]0?#
M7-+>25L?%K.RM86,UW.X7A,[X810/>7'VX8M5=+(XX]4CR&`NJN$>1;8]H+K
MV21[B:,BC&D.=T%,7.[DDT:,:!$^XT)=@N3Y-I:\J#8OD5Y-#68MDDHM)/C3
MN7'E@HI*BE1YM2CU<H6F]@HF_@7NX15X_P!Y_3KR"SWV7EO@3<+&3AVZ;A*V
M';K^1UK(R:I?(VSDTR,DMZZC$V7VI(Q^'ZJ-KY:VY?9RVK;#E$4K=Q@B;JFB
M`>TMP`,@J"U^6HMU`G'!*;A>%66.EK,GV9D=4((+&1!K85$0MS`@9!!8]P39
M#,<.,U0P3L1Z!"QZ/5J*Y_9Z+RYP/@VY\8EM>6>5=QLHXF73XH(K1SKJ&&\B
M!+77DI$8+8G@.]J-CPXM!<_1GZ_NFYV]X'V.Q0R%Q8'.=(-#G1NS$;<<7##4
M2*#(51%V[ET5TF9"RFB@CLV-0C+W&S_9NGQS)WQYZ`>LJJMHLH?#FD:@GJGI
MWHJ*B>A>9.9VL<\]MS#;K9FZ-;47=B_VC,QPJR8-)?;W$;V^IKQ[;B,-8(('
ME>.[=(6M?82O,'_;D&K21FVN#V$'`C'Y)G^O)P)._M3I&D?<#78F,JBN$X)6
MHEF%>"#5Q&(O_E>Y.NC7B>^MMP_4QP^:TE]V$<DLLVEKA^,,'"I;]K7.'R7*
M&\POBX9N(D;I=_!2]:CZ3EE_M`4ZR_5?Z5Z^AXYKJ2,EP,IR>APG&,CS/*;$
M%1C.(T5ODV16LEW;'K:.B@2+2UG'=^@46#%>]?V-ZBJKY?'3XM:H^08GDIY^
M^6NH,<V8GD9N:UCZ2QW/X)[6-AVIM=^]C-.ZJ$4PQ-66X3:][N%_Y/W-X0CN
MZY+-Q(](4DTOXI?CHEQ)43_M"TS"^ZC'C?>0,;^UG1/N!/#]S"DCD>Y'E@[^
MX9&^K'HBIZIU%C4]U5A^/#+;[XZ?EBE:3SRQ+`QZTSK)_&;-Y,AR!B6-9D=F
M$FK<KD.*K1I'E7@J66TR^C(LXJ\HCEZJV.Q:KTBIPJHOU1>/ZNHM2T;+_EEE
M_P!.G_[H;HBHN?!&JI\F>+\*J?\`X#>7T_Z6B_\`BG56YWTJ<GYPOCQ!Y(Z?
MD>2.J\<&??&EJ:1*OX57$1;+:&JH3'RKBE.(3%?9Y%AHD?/JU7DI`))B-[E*
M)&E@PTP2!?`K\B_\^XU$\)-P7_O9CAM2>;H#(;.0KSY7@M>)TF?KHTLSU?(N
ML(BHIJU%57&ID<)/_I?C%5XZA6(-OZZKMO:GV=JBV(T-;LO`,OP.:=S5>D8&
M5T$^D=*[4]7+%6:A$_:WJ+6,#54>/B=V18^$/R85.N]RH[$274_,O&/8J62I
M%!39/96<(>-S)9#J,3*Z3FN/P1L.Y4&L:<A>>Q>>JMKA5N"OF*G"JB_5%X7_
M`$=1:ECHBRB<JB)]57A/]/1$DVH-WZSWQ3Y5D&JLB3*J+#=A9=JZXN`09\2M
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MXA=RN+;M;<AX[;WL1!=[88\=6R-`#FGMW'=I!ZHSXMLR0*)'JF%<*$TS"I%:
M_A9<OCVV29;DX]Z0WN[1HOX1-7AJ)RY7>;X;Y?O=OM8MA<7,V\/!$=?[V3(2
M2'#6_'2P?3&TT8!5Q=X[<N/,?(;D@&6E*]AV'8=3U.9Z4=#1;E`/(\*C"F-6
MMQB;4P@(UW#"D6>(]S-5.>%=-F%)^+_VFL3]'7<+CWG7;O\`5&PVD-P/RO:;
MBWB8`?2YQF:^YE^<LKGX]8VL'1<>W?&)3974A;^-.Q[CW`TD,']5H'VU7$D;
M=$6'D=)(E(Z-<&?8Q.Y_*1[N"8IXI6JJ_A^]C/+&?^OW&*O[O7K]UYNL76.Z
M;#<3:[:^D,\=3@RZB<Y\;AC_`(K"^!W?6PGZ5_4SC,@EAN6MHZ,:7?%C@`?^
MDT=]A[IM66[+/80EK2%<>*%2.@]SE4L%Y'=Q6Q7KZMC'=ZD%^XKOQ(B.]5ZE
M\U\M7O(+,[-4R6+2XQ&N,)=B=!_<><7QGTD^MNE]2??]LX^R"07%*2&FKL[Y
M]R.ASZ&H1E\3,*M\^WMB<\`B+687-'E][-[5]F*&N[W5L9[_`-W[BQL_;8QG
M/+FH]R>C%X]^_1CX]W?G?GS9[ZT8[\KV*<;C=RT]+!%7V&$Y:YIRQK6YEC9'
M`485_#Y&W6VVCB5Q"\CW[IGLQMZG5]1^36U)/>@ZJ<.RL(=37V%M8F^W@5<*
M78SY'MF-[$.#')*E&]F.,L@OM`$YW:QKGNXX:BKPG7T"9KJ:JRGRM_(W;>0V
MB;[QO\+M6[_V%6[#6-#V?MN%H_:=/C@L,"4,XN)8NRUQ2'=6DO)Y(1BG25CA
MC"KVD$QQG'7VJMC6TQ*DE^,CRC\?LGT9HCQFPJGV5KS9NM]-T59?:VV%JC86
M(2XEABE76Q\TLQ9):XY'Q&T#-R"822P@YWO2$D=WMH_O8V+%P-:]%(ULG8V'
MZBP7)=DY_9R*;#<1@-L[^SB4UWD$F'#=)!$:0-+CE=;7=@Y9$EC>R/'*].>5
M1&HJH6(%<`J0GRRVL/RS\PC;I\3=1>0>0T[L"P^JRO-`Z/V=1BN\]Q299QX6
M0T$6;C,>X:&%CK*R.DHX`.>:*G8U6L1[JMK<!BK!GA3\MF,[$Q/7VM_*K7.Z
MM)>0+FT&&V=AD.E]EEP+/\CD%B4L"]JKZMQF9_+LG(IA&%DQ;,44,0Q'(PQ!
M)WH6);U&2<IY7_)%HKQKDYOKPU%M_9VY*2E<R/KG66GMAY*IK6ZHVV%!&FY>
M+'AX7#A2QS0N,9LXSP#<[_9O(U1]10-)^2J,?&]DVU?"_P`OL(\A-J>-?D5,
MP*+5YMCN6NQ_3>>2+2KA9O5&C)<5T691PPV3:N>@GD![K"$C]_9R]&M=5L-#
MAA57=O'CRBTYY28]<Y'I^WR2QB8Y-A5>10<LU_G.OK>GL+&&LZ-"E5><X_0G
MDN?%15<Z.AQ-XX5W*HBQ:B*9JH7\I?@;M#PC\N<7WWXKX]E\?!-@9?\`XCZP
ME:]H+2\G:FVM3SAW-UB;(=-"F/BT[Y;_`+^J80:`)",:'PYD=R.JV-=48J>;
MQE^8#`,ZQ;$*?R<T[OSQTVQ,!5U=R2ZT5M2SUG?7LAX('YEC&24V+V4JMK;6
M8]")'LH\=8GN>VI3-9[KE%@6]LD0/E9^("O\RY;]Z:*G4F%>2%?7`A7L&W*2
MMQ7;M?5!0=4&XLX@BEQ_-:F.)H(5IV$&8+1@D]K!B,&*M=3`Y)(_%7Y3=N>+
M512>/?RI:BV[JS(,4%'Q[&_(^7A5SD6)9540FI&A/SNVQT%I"GVD6.-&+=5)
M)X9[41\D83(0I:J6UQ:I+W?*E\<S:AEY_P!Y&C70GC]QH19:PUNJ<(O9_+XH
M[[Y#>O\`Z:QO<Y]..HL=+NRBV\UOEZV%N'"\DT[\;&F-\;.M\GB3,?N?(2FU
M'GBU%#636/C3%UA7I1/L9M_-C/<P-K.'$#!1WN`&8G80=60;3%R>AXDYAK?X
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MQDD2VQ@\:-,QO'+#&X,B:=I0M29.C*)41[^UBM<I5H)Q"IT_'1M/R?\``CR!
MKMR1/&G?V4ZYO:&3AFS\8CZMSN/,O,(FRXTT%C639&/-KOYDQNRABEQ5*]@3
M*A0.>-IU(VK8ZAPZJV)__7SPQ_DS^:OO=Y?G/L=_^&G_`&W[I_Q&^Z]OW/R[
M\K_D[\D^X[OP>[^8?9]WK[W;^+J+7I*?7M/3.OMR5(:O.*=99(7N.JKB"98-
MY4/-V^ZL"P8URH(O:G>$C2`>J(KF*J(J<1^6_!WCCS;M#-JY[8^])!4P7,3C
M%=6Y=3489@"0'4&J-X?$Z@+F$@$>>V#D^\\9N#/M4ND.^ICAJC?3+4WX="*.
M'0A,]+\=^,,E/-7;3R>(%'JX`ST-3*.).>6HZ0*5#81S?XD&W^CKI-<_RT.)
MFZ,NW\LW6&`.JP/M;>1[>U7M=&"1W#&_)<EM\TWYC#9MO@<ZF-)'@'["'4_:
M5LQO`*NBO$06W+_N$]A&<XO6_O,<CF\\6J*J<IUC;?RUMELY636_,MR:YC@X
M?Y*&E6FH_P`;NM;_`#%/("UVVPT(I_>N_LKR3X_ZTB\KMW($5'=R*F,5O*.Y
MY147\T^J+UK=_+2V-S];^9;F7`U_]*'.M:_WW=9-\R3M%!ML/_E=_97B#\=^
M'MFB/<;+RJRB(_N/%B4]16G.WGE6-F$+8H'N_6@E7]77]FV?RT>$07K)=XY1
MNUS8AU7QQ6]O`YPZ@2$S::]]!/:B3>:=S=$66UC;LEI@2][@/ZOIK^U/4UWK
M+"=54#<<P>D!45ZD:>67O?)L;26C.Q9EI8G5TF;(5OHG<O:Q/PL:UOIUWK\:
M>*N">(>/#C/`K".RV\N#I'5+YIY*4]R>9Y+Y7TR+C1H]+`UN"XMWK?MUY#>&
M]W64R39`9-8/W6-&#1\L3F22C[UR(O$+6GV4.JAR+&TL(M97Q!N+*GV$L,*'
M'$QJN>0\F2081,:U.5553TZ(OL&0.4`4@!FGCR!#.`PW^X(P2L0@BC>BJUXR
M,<CFJGHJ+ST1>^[MX7N1OJB(JN1OJY4:U$551.7.5$1/TJO'1%Z[W_Q._K7H
MB'>_^)W]:]$0[G(G".<B?L5>B(=[_P")W]Y?[>B+"N54Y<J\-15557T:B>JJ
MJKZ(B)]5Z(M"MMZRV"6146<&SC@E'@GD5LP$P`IL1W9*B$-&(0:2(SU[2,Y[
MF.]%X7HBZ'>_^)W]Y?[>B+ST1?"5&C3HQ84Z-'FPSL49XDP`I44S%7E6%CG8
M01&JOZ%14Z(B('4>J(\O[^/J_7()W=W?>AP?&!2^[GGN^X95M-W<_IYZ*U*4
M$;6A&P06M"(36L&(+6B$-C4X:Q@QHUC&M3Z(B<=%%Z1SDYX54Y^OJOKT19[W
M_P`3O[R_V]$6%557E555_;T191SD]$<J)^Q>B(=[_P")W]Y?[>B(=[_XG?UK
MT1>>B(=$0Z(AT1#HB'1$.B)A_E`S$\[VSJ37%V2LAU6-LG;*V3D%C)9&C4V$
M5KVM!5S)!"-CA#>3`JQ6O3N5[Q=OU]:LVX`E/!PG/<,V+3.O\%OJ_(:0,PU8
MZ77(9@02XC!*2(X,@,<PG#$5CFHK$1S'(K>45%ZBQ((S28;A!I_8%CB^HLZS
M,U7DDZ_KLAH:"BNI%=>3)]6,\B,*2Z)'DL!'D1W/5C3^TYRHCQ*CVM=T5%1B
M$N%E95U-7R[2WGPZNKKH[I,ZQL90XL*'&"U.\\J7)>T8AM3ZN<[Z_MZ+'-%?
M%-C83FYCQL7OP6<F-!BVCXSHMC7R25,XA!0[>("TAP2SZB44+FCE`0D=SDX1
M_/14@C-<G<&R8&I-=Y'G<X(II*B(U*RJ));%=<6\HPHM?7")VO>GNG,BD5C7
M.8)KG<>G1`*FBY6J=RXILVOA0P6]2+.@4-;;Y1B$9;(4ND+-")YAB'<0*Z5-
MB13&:-QV,<SN5/7A6JI"*'X(L>5N05F.Z&SP]C##8'M84?'J."9'K[^074AD
M.L(%!O8]3P7N=):B+]0_I3HJW-<W2V3:JUGC^`Z&9FF/IGL"J#&GT03.><^4
M2ADM;Z*^4$+J]+)L\Q44#C(=.U&]O/"=$-3ZNB<UT6*37(-Q:PQ>R@TMQFE,
MRZL;F)CT.F@&?<6Q;B<9``ANKJD<R4%R%<B$<]K6BY3O5O*<E:%&W)LGQ[#:
M:;D.57$&AI:]O=+L;$R!CB555&#;PCB&.5R<,&-KB/7T:B]%`*Y(B!WKJ"1-
MP^M!L#'R6&?!CR,1A-+(^YN`RSOBQ'L"L9'PTERAN$+[E`J0C5:WE4Z*T.:.
M&7YKB>`4ILAS._KL<I@/:)TVQ*K&O,_]T$<`V%DRY#D15]L3'O[45>.$5>B@
M!.2*YMUZG!<XSCQ,\H/SK,15AL<KAG,8]@.Z$(]0KO9`0<%]D$['!;)<%ST>
MU43U3HK0YK=QW;.M\MR:TPW&<RI;S):8!95C5UYB'>&.`PXYRCDH)(4M@#F:
MQZA*3L5?7CHE"E"54:BN<J-:U%<YSE1K6M:G+G.<O"-:U$Y55]$3HHDX%N#6
M<G*:;"8&94]ME%\LY*VJI2DN'N2M`^3,)*D5HY,2`$01N5'G(-CU:J-551>B
MM#2J4CHHAT1#HB'1$.B(=$0Z(AT1?,I1`$4YWH(`!$.8COW1A"QQ"O7]C&-5
M>B*.[6"XKD$K9/EOM%$LJZ^R634:TQ,PTFNF1<>D+58W'@T_:];K(Y\F.T$`
M",>@3(0_".5'CJS-?I"<WXZ:^ML!P6;(R2("LRG.\IN]@Y%3QT&V)C\S(#,)
M&H1>TOL\5%>$0RJW\/O=Z)Z(G44<:E(1I]F*['W]>;#`@1XUB1<FQG4\%RR)
MTS(KD9ON-A;'G22)(DE&^1,;%#+DO1BH40!N1PFL0J:@(X;S#*V%O+2&EIZ$
M_D>:"XV1ET).Y(^1MQ8CUK*><B*B'@BF1VJ02_A=[Z*J<HU4*#`$]5C"9LC8
M?EAFV8T2J["-7X$/5OYG&3BMM<DD6++2QKHA&*@I#:DSB-)V<M&X;/IWIS>B
M'!M.ZY&_Z:JV9OO1FJOLHL@D4DG8.92GL:60+%Z`IB5U0CE[EC@M9S#-(UJ(
MI>\?=RC6]%6U`)71Q^N/G7F1EF=5*(N,ZPP8&!V5L#UBV>76#7R95,PS>&R3
MTX)SON$15]EXF-=PJIU$R;0KD^1-?)VWN/56EH5F2KI<:CR=L;!M@&8):FLA
ME2%4JIB(H8TPB,,P+W^@W2&D^C>JHW`57;RK!JK)]]Z0QC#JR#`Q?2578YWD
M4FL&+[2`6Z=&'BE.22SN619W4BO=,?WO<4@>X[U57HYT2N!KU1VVMG+9V>XU
MI:)?IBP+>@L\XV+DS)PZR74X#4/4+JNLL'D$M=/R26UPBRFN0D2$PCV*CW-<
MT@&%4AVO[_$-K;^J9M57Q*76.E&S<4UA5"KGQER+/K>*0]I=BKVA60*/64]>
M\WNE:GM)[)3.:0R)T5-0W',I1O,:Q9&UU64E57LL\]SNZ9@&$@[GO/'?DJ"#
MD$N)'[E`V0^H"L7[A6*0#)3D:YK7O[BC<_@E1U=I'#]=X=B5!)IZ>]O<<;#L
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M6^PPJ=1ES7)[U'FH\2*(+DES**OCB]R1$$CG6,P@H[FN&CF/*`4%>I1)\<+J
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MM@S1K43:ZWA0LB%(8A$54$56O:J=R>E63L``GMX]CE#B=3%HL:J85+40T?\`
M;P(`D$%KRO4ASD55<61*DE<KRF(YY2O57/<JKSU%AFBY:ZOP"[DYC-M,7@3)
MNP*:-CV83"/EI)NJ6&%01:\IF2&NC``-?P^Q[2]R(Y>51%Z*U*ZN(87BV`TD
M?'<0I8M'41N'-C1U*4AB(Q@D/,F22&F3I/M#:SW"D>Y&-:U%1J(B%"2<UP,@
MU%K;*\OJ<\R3$:RYRJCB#A5ME.]\PP@`<LF,A:]3?ETPD0YGN$\PGN&KEX5/
M3@K4@4Z+8Q#5N`8'9Y!=8GC,&HM\IGRK*\L6/DR9<R3-D.ERFL-,/(=$BFE.
M]QP0^V)7<+V^B<$))P7:M<.QB\OL;R>WIHEA?8@^>3&;&3[KR4Q;,+`3C1!(
M5(WO'"-&][F.>U$_"J=$J<D9>BB*\/"L5@99;9W$I(8<OO*^'4VE_P`F)/E5
MD#L6)!12E>*/&$HFJK1,8CE:BNY5.BM32G1<>'JO7U?BF181`Q>#"Q?+2VQ\
MDK(Q)@_S>1>-[;23+F+)=/=)E-1$[T*CF(B(WA$Z)4KL8?A6*X!1QL;PZDA4
M--%]61(;7JXA.UK%/+DG>67-DN8U$4A7O?VHB<\(B=$))S18=IC5Q,QN,_-A
ME5(R^^CNC6=S)^YD%(Q\-*\I8\<LAT.#+/"3VGG",9G-_P!;U7DE3ET78P+6
M^$:PIW4."8]#Q^L(;WSC`^1(D2C<N[7RYTPLB;*]I'JC$>16C151J)RO1"2<
(T=^BB'1%_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
